September 16 (SeeNews) - Bulgarian drug maker Sopharma [BUL:3JR] said on Wednesday that its CEO - Ognyan Donev, further increased his interest in the company through a single transaction on the regulated market of the Bulgarian Stock Exchange on September 15.
Donev bought 331 shares in Sopharma in a deal priced at 3.14 levs ($1.91/1.60 euro) per share, the drug manufacturer said in a bourse filing.
You can subscribe to our M&A newsletter here
Donev has directly acquired a total of 99,000 shares in Sopharma, or 0.073% interest, so far this month.
Indirectly, Donev is the biggest shareholder in Sopharma, as he controls a 25.67% stake through Donev Investments Holding. Donev is also a major shareholder in Sopharma's second-biggest shareholder - Telecomplect Invest which controls 20.68% interest in Sopharma.
As at 15:00 CET on Wednesday Sopharma's shares traded 0.64% lower at 3.12 levs on the Bulgarian Stock Exchange.
(1 euro = 1.95583 levs)